• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

老年转甲状腺素蛋白心脏淀粉样变患者的步态异常。

Gait abnormalities in older adults with transthyretin cardiac amyloidosis.

机构信息

Department of Mechanical Engineering, Columbia University, New York, NY, USA.

Department of Medicine, Division of Cardiology, Columbia University, New York, NY, USA.

出版信息

Amyloid. 2024 Jun;31(2):116-123. doi: 10.1080/13506129.2024.2319133. Epub 2024 Mar 3.

DOI:10.1080/13506129.2024.2319133
PMID:38433466
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11116048/
Abstract

BACKGROUND

Transthyretin cardiac amyloidosis (ATTR cardiac amyloidosis) is caused by variant (ATTRv) or wild type (ATTRwt) transthyretin. While gait abnormalities have been studied in younger patients with ATTRv amyloidosis, research on gait in older adults with ATTR cardiac amyloidosis is lacking. Given ATTR cardiac amyloidosis' association with neuropathy and orthopedic manifestations, we explore the gait in this population.

METHODS

Twenty-eight older male ATTR cardiac amyloidosis patients and 11 healthy older male controls walked overground with and without a dual cognitive task. Gait parameters: stride width, length, velocity and stance time percentage were measured using an instrumented mat. ATTR amyloidosis patients were further categorized based on clinical and functional assessments.

RESULTS

We found significant gait differences between ATTR cardiac amyloidosis patients and healthy controls; patients had more variable, slower, narrower and shorter strides, with their feet spending more time in contact with the ground as opposed to in swing. However, the observed gait differences did not correlate with clinical and functional measures of ATTR cardiac amyloidosis severity.

CONCLUSIONS

Our results suggest that gait analysis could be a complementary tool for characterizing ATTR cardiac amyloidosis patients and may inform clinical care as it relates to falls, management of anticoagulation, and functional independence.

摘要

背景

转甲状腺素蛋白心脏淀粉样变(ATTR 心脏淀粉样变)由变异型(ATTRv)或野生型(ATTRwt)转甲状腺素蛋白引起。虽然已经研究了年轻的 ATTRv 淀粉样变患者的步态异常,但缺乏对老年 ATTR 心脏淀粉样变患者步态的研究。鉴于 ATTR 心脏淀粉样变与神经病和骨科表现有关,我们探索了该人群的步态。

方法

28 名老年男性 ATTR 心脏淀粉样变患者和 11 名健康老年男性对照者在地面上进行了有和没有双重认知任务的行走。使用仪器化垫测量步态参数:步幅宽度、长度、速度和站立时间百分比。根据临床和功能评估,进一步对 ATTR 淀粉样变患者进行分类。

结果

我们发现 ATTR 心脏淀粉样变患者和健康对照组之间存在明显的步态差异;患者的步伐更不稳定、更慢、更窄、更短,双脚与地面接触的时间更长,而处于摆动阶段的时间更短。然而,观察到的步态差异与 ATTR 心脏淀粉样变严重程度的临床和功能测量无关。

结论

我们的结果表明,步态分析可能是一种补充工具,用于描述 ATTR 心脏淀粉样变患者的特征,并且可能与跌倒、抗凝管理和功能独立性相关的临床护理有关。

相似文献

1
Gait abnormalities in older adults with transthyretin cardiac amyloidosis.老年转甲状腺素蛋白心脏淀粉样变患者的步态异常。
Amyloid. 2024 Jun;31(2):116-123. doi: 10.1080/13506129.2024.2319133. Epub 2024 Mar 3.
2
Transthyretin amyloidosis: Putting myopathy on the map.转甲状腺素蛋白淀粉样变性:肌病的研究进展。
Muscle Nerve. 2020 Jan;61(1):95-100. doi: 10.1002/mus.26723. Epub 2019 Oct 21.
3
Clinical and genetic profiles of patients with hereditary and wild-type transthyretin amyloidosis: the Transthyretin Cardiac Amyloidosis Registry in the state of São Paulo, Brazil (REACT-SP).巴西圣保罗州转甲状腺素蛋白心脏淀粉样变登记研究(REACT-SP):遗传性和野生型转甲状腺素蛋白淀粉样变性患者的临床和遗传特征。
Orphanet J Rare Dis. 2024 Jul 20;19(1):273. doi: 10.1186/s13023-024-03281-z.
4
Amyloid myopathy: expanding the clinical spectrum of transthyretin amyloidosis-case report and literature review.淀粉样变心肌病:转甲状腺素蛋白淀粉样变性的临床谱扩大——病例报告及文献复习。
J Nucl Cardiol. 2023 Aug;30(4):1420-1426. doi: 10.1007/s12350-022-02990-x. Epub 2022 May 17.
5
[Neurological manifestations of ATTR amyloidosis].[转甲状腺素蛋白淀粉样变性的神经学表现]
Inn Med (Heidelb). 2023 Sep;64(9):848-854. doi: 10.1007/s00108-023-01570-6. Epub 2023 Aug 9.
6
Frequency of hereditary transthyretin amyloidosis among elderly patients with transthyretin cardiomyopathy.老年转甲状腺素蛋白心肌病患者遗传性转甲状腺素蛋白淀粉样变性的频率。
Eur J Heart Fail. 2022 Dec;24(12):2367-2373. doi: 10.1002/ejhf.2658. Epub 2022 Sep 11.
7
Quality of life assessment in amyloid transthyretin (ATTR) amyloidosis.淀粉样变转甲状腺素蛋白(ATTR)淀粉样变性的生活质量评估。
Eur J Clin Invest. 2021 Nov;51(11):e13598. doi: 10.1111/eci.13598. Epub 2021 May 22.
8
First Norwegian case of hereditary ATTR amyloidosis with a novel transthyretin variant.首例挪威遗传性ATTR 淀粉样变伴新型转甲状腺素蛋白变异。
Scand Cardiovasc J. 2023 Dec;57(1):2174269. doi: 10.1080/14017431.2023.2174269.
9
Prevalence of transthyretin cardiac amyloidosis in patients with heart failure with preserved ejection fraction: the PRACTICA study.射血分数保留的心力衰竭患者中甲状腺素运载蛋白心脏淀粉样变的患病率:PRACTICA研究
Rev Esp Cardiol (Engl Ed). 2025 Apr;78(4):301-310. doi: 10.1016/j.rec.2024.07.005. Epub 2024 Jul 31.
10
Clinical and apparative investigation of large and small nerve fiber impairment in mixed cohort of ATTR-amyloidosis: impact on patient management and new insights in wild-type.混合队列 ATTR-淀粉样变中大、小神经纤维损伤的临床和仪器研究:对患者管理的影响及野生型的新见解。
Amyloid. 2022 Mar;29(1):14-22. doi: 10.1080/13506129.2021.1976751. Epub 2021 Oct 11.

本文引用的文献

1
2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis: A Report of the American College of Cardiology Solution Set Oversight Committee.2023年美国心脏病学会关于心脏淀粉样变性患者综合多学科护理的专家共识决策路径:美国心脏病学会解决方案集监督委员会报告
J Am Coll Cardiol. 2023 Mar 21;81(11):1076-1126. doi: 10.1016/j.jacc.2022.11.022. Epub 2023 Jan 23.
2
Prevalence of Orthopedic Manifestations in Patients With Cardiac Amyloidosis With a Focus on Shoulder Pathologies.心脏淀粉样变性患者的骨科表现患病率:重点关注肩部病变。
Am J Cardiol. 2023 Mar 1;190:67-74. doi: 10.1016/j.amjcard.2022.11.014. Epub 2022 Dec 23.
3
Transthyretin Cardiac Amyloidosis: An Evolution in Diagnosis and Management of an "Old" Disease.
转甲状腺素蛋白心脏淀粉样变:一种“古老”疾病的诊断和治疗的演变。
Cardiol Clin. 2022 Nov;40(4):541-558. doi: 10.1016/j.ccl.2022.06.008. Epub 2022 Sep 15.
4
Gait in Cerebral Amyloid Angiopathy.脑淀粉样血管病的步态。
J Am Heart Assoc. 2022 Oct 4;11(19):e025886. doi: 10.1161/JAHA.121.025886. Epub 2022 Sep 21.
5
Analysis of lumbar spine stenosis specimens for identification of amyloid.分析腰椎管狭窄症标本以识别淀粉样蛋白。
J Am Geriatr Soc. 2022 Dec;70(12):3538-3548. doi: 10.1111/jgs.17976. Epub 2022 Aug 5.
6
Gait Characterization and Analysis of Hereditary Amyloidosis Associated with Transthyretin Patients: A Case Series.遗传性转甲状腺素蛋白相关淀粉样变性患者的步态特征与分析:病例系列
J Clin Med. 2022 Jul 7;11(14):3967. doi: 10.3390/jcm11143967.
7
Assessment and Management of Older Patients With Transthyretin Amyloidosis Cardiomyopathy: Geriatric Cardiology, Frailty Assessment and Beyond.转甲状腺素蛋白淀粉样变心肌病老年患者的评估与管理:老年心脏病学、衰弱评估及其他
Front Cardiovasc Med. 2022 May 17;9:863179. doi: 10.3389/fcvm.2022.863179. eCollection 2022.
8
Clinical features and predictors of atrial fibrillation in patients with light-chain or transthyretin cardiac amyloidosis.轻链或转甲状腺素蛋白心脏淀粉样变患者心房颤动的临床特征和预测因素。
ESC Heart Fail. 2022 Jun;9(3):1740-1748. doi: 10.1002/ehf2.13851. Epub 2022 Feb 17.
9
Supporting the Assessment of Hereditary Transthyretin Amyloidosis Patients Based On 3-D Gait Analysis and Machine Learning.基于 3-D 步态分析和机器学习支持遗传性转甲状腺素蛋白淀粉样变性患者的评估。
IEEE Trans Neural Syst Rehabil Eng. 2021;29:1350-1362. doi: 10.1109/TNSRE.2021.3096433. Epub 2021 Jul 20.
10
Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases.心脏淀粉样变性的诊断与治疗:欧洲心脏病学会心肌与心包疾病工作组的立场声明
Eur Heart J. 2021 Apr 21;42(16):1554-1568. doi: 10.1093/eurheartj/ehab072.